Long term data from Phase II stroke clinical trial confirm positive results seen after three months.
Results indicate that CTX cell therapy has potential to improve long term outcomes in disability, dependence and motor function in disabled stroke patients.
31 October 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today provides an update regarding the Company’s Phase II clinical trial (PISCES II) of its CTX cell therapy candidate for stroke disability and, in addition, an update regarding its global clinical and regulatory development strategy for the stroke programme.